Attenuation of neuroinflammation and Alzheimer's disease pathology by liver x receptors

Alzheimer's disease (AD) is an age-dependent neurodegenerative disease that causes progressive cognitive impairment. The initiation and progression of AD has been linked to cholesterol metabolism and inflammation, processes that can be modulated by liver x receptors (LXRs). We show here that endogenous LXR signaling impacts the development of AD-related pathology. Genetic loss of either Lxrα or Lxrβ in APP/PS1 transgenic mice results in increased amyloid plaque load. LXRs regulate basal and inducible expression of key cholesterol homeostatic genes in the brain and act as potent inhibitors of inflammatory gene expression. Ligand activation of LXRs attenuates the inflammatory response of primary mixed glial cultures to fibrillar amyloid β peptide (fAβ) in a receptor-dependent manner. Furthermore, LXRs promote the capacity of microglia to maintain fAβ-stimulated phagocytosis in the setting of inflammation. These results identify endogenous LXR signaling as an important determinant of AD pathogenesis in mice. We propose that LXRs may be tractable targets for the treatment of AD due to their ability to modulate both lipid metabolic and inflammatory gene expression in the brain.

[1]  M. Roth,et al.  The Liver X Receptor Ligand T0901317 Decreases Amyloid β Production in Vitro and in a Mouse Model of Alzheimer's Disease* , 2004, Journal of Biological Chemistry.

[2]  M. Irizarry,et al.  Induction of the Cholesterol Transporter ABCA1 in Central Nervous System Cells by Liver X Receptor Agonists Increases Secreted Aβ Levels* , 2002, The Journal of Biological Chemistry.

[3]  C. Glass,et al.  Promoter-Specific Roles for Liver X Receptor/Corepressor Complexes in the Regulation of ABCA1 and SREBP1 Gene Expression , 2003, Molecular and Cellular Biology.

[4]  D. Teplow,et al.  Cyclooxygenase-2 promotes amyloid plaque deposition in a mouse model of Alzheimer's disease neuropathology. , 2002, Gene expression.

[5]  B. Zlokovic.  Clearing amyloid through the blood–brain barrier , 2004, Journal of neurochemistry.

[6]  S. Paul,et al.  Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition , 1997, Nature Genetics.

[7]  M. O’Banion,et al.  The role of COX-1 and COX-2 in Alzheimer's disease pathology and the therapeutic potentials of non-steroidal anti-inflammatory drugs. , 2005, Current drug targets. CNS and neurological disorders.

[8]  E. Génin,et al.  ABCA2 is a strong genetic risk factor for early-onset Alzheimer's disease , 2005, Neurobiology of Disease.

[9]  C. Glass,et al.  Activation of liver X receptors and retinoid X receptors prevents bacterial-induced macrophage apoptosis. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[10]  D. Mangelsdorf,et al.  An oxysterol signalling pathway mediated by the nuclear receptor LXRα , 1996, Nature.

[11]  Rena Li,et al.  Microglia and inflammatory mechanisms in the clearance of amyloid β peptide , 2002 .

[12]  J. Palmgren,et al.  Genetic variants of ABCA1 modify Alzheimer disease risk and quantitative traits related to β‐amyloid metabolism , 2004, Human mutation.

[13]  H. Wiśniewski,et al.  Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[14]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[15]  J. Serratosa,et al.  High‐yield isolation of murine microglia by mild trypsinization , 2003, Glia.

[16]  Rachel M. Adams,et al.  Differential Gene Regulation of StarD4 and StarD5 Cholesterol Transfer Proteins , 2005, Journal of Biological Chemistry.

[17]  S. DeKosky,et al.  22R-Hydroxycholesterol and 9-cis-Retinoic Acid Induce ATP-binding Cassette Transporter A1 Expression and Cholesterol Efflux in Brain Cells and Decrease Amyloid β Secretion* , 2003, The Journal of Biological Chemistry.

[18]  P. Tontonoz,et al.  Liver X receptors as integrators of metabolic and inflammatory signaling. , 2006, The Journal of clinical investigation.

[19]  Peter Tontonoz,et al.  LXR-Dependent Gene Expression Is Important for Macrophage Survival and the Innate Immune Response , 2004, Cell.

[20]  R. Hammer,et al.  Cholesterol and Bile Acid Metabolism Are Impaired in Mice Lacking the Nuclear Oxysterol Receptor LXRα , 1998, Cell.

[21]  R. Mahley,et al.  Apolipoprotein E: far more than a lipid transport protein. , 2000, Annual review of genomics and human genetics.

[22]  D. Borchelt,et al.  Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. , 2001, Biomolecular engineering.

[23]  Xianlin Han,et al.  ABCA1 Is Required for Normal Central Nervous System ApoE Levels and for Lipidation of Astrocyte-secreted apoE* , 2004, Journal of Biological Chemistry.

[24]  S. Kliewer,et al.  Regulation of cholesterol homeostasis by the liver X receptors in the central nervous system. , 2002, Molecular endocrinology.

[25]  G. Landreth,et al.  Microglial Phagocytosis of Fibrillar β-Amyloid through a β1 Integrin-Dependent Mechanism , 2004, The Journal of Neuroscience.

[26]  Douglas R. McDonald,et al.  Amyloid Fibrils Activate Tyrosine Kinase-Dependent Signaling and Superoxide Production in Microglia , 1997, The Journal of Neuroscience.

[27]  J. Gustafsson,et al.  Liver X receptors in the central nervous system: From lipid homeostasis to neuronal degeneration , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[28]  D. Mangelsdorf,et al.  Liver X receptor signaling pathways in cardiovascular disease. , 2003, Molecular endocrinology.

[29]  B. Wolozin,et al.  Cholesterol and the Biology of Alzheimer's Disease , 2004, Neuron.

[30]  A. Hoffmann,et al.  Molecular Determinants of Crosstalk between Nuclear Receptors and Toll-like Receptors , 2005, Cell.

[31]  J. Adamski,et al.  Analysis of the 5′ flanking regions of human and murine HSD17B7: Identification of a cholesterol dependent enhancer region , 2006, Molecular and Cellular Endocrinology.

[32]  Brian J. Bacskai,et al.  Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease , 2006, Neurobiology of Disease.

[33]  I. Hinners,et al.  System Xc− and Apolipoprotein E Expressed by Microglia Have Opposite Effects on the Neurotoxicity of Amyloid-β Peptide 1–40 , 2006, The Journal of Neuroscience.

[34]  Lilit Vardanian,et al.  The effects of ABCA1 on cholesterol efflux and Aβ levels in vitro and in vivo , 2006, Journal of neurochemistry.

[35]  D. Hinton,et al.  Liver X receptor activation decreases the severity of experimental autoimmune encephalomyelitis , 2006, Journal of neuroscience research.

[36]  J. Collins,et al.  Therapeutic opportunities for liver X receptor modulators. , 2004, Current opinion in drug discovery & development.

[37]  Aldons J. Lusis,et al.  Identification of macrophage liver X receptors as inhibitors of atherosclerosis , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[38]  J. Koenigsknecht-Talboo,et al.  Microglial Phagocytosis Induced by Fibrillar β-Amyloid and IgGs Are Differentially Regulated by Proinflammatory Cytokines , 2005, The Journal of Neuroscience.

[39]  J. Gustafsson,et al.  Inactivation of liver X receptor beta leads to adult-onset motor neuron degeneration in male mice. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[40]  M. Mattson,et al.  Microglial activation resulting from CD40-CD40L interaction after beta-amyloid stimulation. , 1999, Science.

[41]  Tony Wyss-Coray,et al.  Inflammation in Alzheimer disease: driving force, bystander or beneficial response? , 2006, Nature Medicine.

[42]  E. Joe,et al.  Oxidized low density lipoprotein suppresses lipopolysaccharide-induced inflammatory responses in microglia: oxidative stress acts through control of inflammation. , 2006, Biochemical and biophysical research communications.

[43]  J. de Vente,et al.  24(S)-Hydroxycholesterol Participates in a Liver X Receptor-controlled Pathway in Astrocytes That Regulates Apolipoprotein E-mediated Cholesterol Efflux* , 2006, Journal of Biological Chemistry.

[44]  C. Plata-salamán,et al.  Inflammation and Alzheimer’s disease , 2000, Neurobiology of Aging.

[45]  M. Hayden,et al.  The Absence of ABCA1 Decreases Soluble ApoE Levels but Does Not Diminish Amyloid Deposition in Two Murine Models of Alzheimer Disease* , 2005, Journal of Biological Chemistry.

[46]  G. Glenner,et al.  Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein , 1984 .

[47]  F. Jessen,et al.  Polymorphism in the cholesterol 24S-hydroxylase gene is associated with Alzheimer's disease , 2002, Molecular Psychiatry.

[48]  M. Fornerod,et al.  Characterization of the Drosophila melanogaster genome at the nuclear lamina , 2006, Nature Genetics.

[49]  J. Gustafsson,et al.  Accumulation of Foam Cells in Liver X Receptor-Deficient Mice , 2002, Circulation.

[50]  Rachel M. Adams,et al.  The cholesterol-regulated StarD4 gene encodes a StAR-related lipid transfer protein with two closely related homologues, StarD5 and StarD6 , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[51]  T. Willson,et al.  Liver X receptor activators display anti-inflammatory activity in irritant and allergic contact dermatitis models: liver-X-receptor-specific inhibition of inflammation and primary cytokine production. , 2003, The Journal of investigative dermatology.

[52]  James L. Buescher,et al.  Overexpression of monocyte chemotactic protein-1/ CCL2 in β-amyloid precursor protein transgenic mice show accelerated diffuse β-amyloid deposition , 2005 .

[53]  T. Fujiwara,et al.  Liver X receptor agonists inhibit tissue factor expression in macrophages , 2005, The FEBS journal.

[54]  R. Flavell,et al.  Role of CD40 ligand in amyloidosis in transgenic Alzheimer's mice , 2002, Nature Neuroscience.

[55]  M. Staufenbiel,et al.  Lack of ABCA1 Considerably Decreases Brain ApoE Level and Increases Amyloid Deposition in APP23 Mice* , 2005, Journal of Biological Chemistry.

[56]  D. Mangelsdorf,et al.  Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. , 2000, Science.

[57]  D. Wilcock,et al.  Dynamic Complexity of the Microglial Activation Response in Transgenic Models of Amyloid Deposition: Implications for Alzheimer Therapeutics , 2005, Journal of neuropathology and experimental neurology.

[58]  A. Tall,et al.  Expression of Liver X Receptor Target Genes Decreases Cellular Amyloid β Peptide Secretion* , 2003, Journal of Biological Chemistry.

[59]  F. Bistoni,et al.  Immortalization of murine microglial cells by a v-raf / v-myc carrying retrovirus , 1990, Journal of Neuroimmunology.

[60]  Daisuke Ogawa,et al.  Liver X Receptor Agonists Inhibit Cytokine-Induced Osteopontin Expression in Macrophages Through Interference With Activator Protein-1 Signaling Pathways , 2005, Circulation research.

[61]  D. Holtzman,et al.  Deletion of Abca1 Increases Aβ Deposition in the PDAPP Transgenic Mouse Model of Alzheimer Disease* , 2005, Journal of Biological Chemistry.

[62]  R. Breitling,et al.  Closing the gap: identification of human 3-ketosteroid reductase, the last unknown enzyme of mammalian cholesterol biosynthesis. , 2003, Molecular endocrinology.

[63]  D. Mangelsdorf,et al.  The role of orphan nuclear receptors in the regulation of cholesterol homeostasis. , 2000, Annual review of cell and developmental biology.